Adult T-cell leukemia/lymphoma (ATL) carries a dismal prognosis. Experience with allo-SCT for ATL appears encouraging but is limited to Japanese series. This retrospective analysis of the EBMT registry revealed 21 HTLV-I seropositive ATL including 7 acute and 12 lymphoma subtypes. Four patients received auto-SCT and rapidly died from ATL. Out of 17 allo-SCT (4 myeloablative, 13 reduced intensity), 6 are still alive (4 were in CR1 at SCT). Eleven patients died within 2 years, eight from relapse/progression and three from transplant toxicity. Six of seven informative patients who lived 412 months had chronic GVHD. Overall these results indicate that allo-SCT but not auto-SCT may salvage a subset of ATL patients, supporting the existence of graft vs ATL effect also in non-Japanese patients.
INTRODUCTION

Adult T-cell leukemia/lymphoma (ATL) is an aggressive malignancy of mature activated T cells caused by the human T-cell lymphotropic virus type I (HTLV-1)
. ATL carries a very poor prognosis because of intrinsic chemoresistance and severe immunosuppression. [1] [2] [3] [4] [5] [6] ATL usually occurs in individuals from HTLV-I endemic regions, such as southern Japan, the Caribbean, Central and South America, inter-tropical Africa, Romania and northern Iran. HTLV-I causes transformation and clonal expansion of T cells, resulting in ATL in~1-4% of the estimated 10-20 million infected hosts, with a mean latency period of 450 years.
1-6 The Shimoyama classification described four different subtypes (acute, lymphoma, chronic and smoldering) associated with different outcomes, and that require different treatment strategies tailored to the clinical presentation. 7 In aggressive ATL (acute and lymphoma subtypes), clinical trials, mostly from Japan, have demonstrated that combinations of chemotherapy can induce acceptable response rates especially in the lymphoma subtype. However, the overall outcome remains extremely poor due to a high rate of relapse. 8 Similarly, the so-called indolent forms (smoldering and chronic subtypes) have a poor outcome whether they are managed with watch and wait or treated with chemotherapy. 9 We recently reported the results of a worldwide meta-analysis and showed that the combination of zidovudine and IFN-alpha (IFN) is highly effective in the leukemic subtypes of ATL, and should be considered as the standard first-line therapy in that setting. 10 This combination has changed the natural history of the disease through achievement of significantly improved long-term survival in patients with smoldering and chronic ATL as well as in a subset of patients with acute ATL. ATL lymphoma patients still benefit from chemotherapy induction with concurrent or sequential antiretroviral therapy with zidovudine/IFN.
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Because of the high rate of relapse in acute and lymphoma subtypes, allo-SCT is attractive as a potentially curative option. Review of the published literature reveals that allo-SCT has been applied to limited number of ATL patients with all of the reported series originating from one geographical location, Japan. The only exception is the English trial on antiviral therapy for ATL that included six patients who underwent allogeneic transplantation, five of whom were alive at the time of the article publication.
High-dose chemotherapy and auto-SCT has been reported in only 16 ATL patients. 12, 13 All patients relapsed or died from TRM. This treatment strategy is not currently recommended.
A number of retrospective studies confirmed the feasibility of myeloablative [14] [15] [16] or reduced-intensity 17 conditioning allo-SCT in ATL patients. Importantly, a large retrospective study was reported in 2010 and included 386 patients allografted between 1995 and 2005 using either standard or reduced-intensity conditioning regimens. 18 After a median follow-up of 41 months, the 3-year OS was 33%. Interestingly, donor HTLV-I seropositivity adversely affected the disease-associated mortality, specifically for patients who received transplants from related donors. Recently, interesting long-term results of 30 patients who received reducedintensity conditioning demonstrated an OS and PFS rate of 36% and 31%, respectively.
Unfortunately, allo-SCT is rarely performed because of the low CR rate, especially in the acute form, poor performance status, severe immunosuppression and low probability of finding a suitable donor in patients from ethnic minorities. 20 Furthermore, most treatment guidelines recommend the use of allo-SCT for ATL solely based on data from Japan owing to the lack of any published data from outside Japan. [3] [4] [5] 
PATIENTS AND METHODS
We performed a retrospective analysis of transplanted ATL patients in the EBMT registry. Data were available for 21 HTLV-I seropositive patients transplanted between 2004 and 2010 for ATL (10 males, 11 females; median age 48 years, range 21-67, interquartile range 36-52). According to the Shimoyama classification, 7 (33%) patients had acute ATL, 12 (57%) had ATL lymphoma and 2 (9%) had an unknown subtype.
Statistical analyses were performed using R (http://cran.r-project.org). Data were summarized using summary descriptive statistics such as means, medians and ranges for continuous variables, and numbers and percentages for discrete variables. Kaplan-Meier curves were used to analyze the OS and PFS of the patients.
RESULTS AND DISCUSSION
Four patients received auto-SCT (three females, one male; aged 32, 33, 49 and 67 years old), all of whom died from relapsed/ refractory disease in o1 year (respectively at 1, 2, 9 and 11 months). These patients were in first CR (CR1; n = 3) or in first PR (PR1; n = 1). These results are in agreement with Japanese and North American results and indicate that auto-SCT should not be recommended for ATL.
Seventeen patients (nine males and eight females) received allo-SCT (Table 1) . Median age was 47 years (range 21-58) at SCT. ATL subtypes consisted of acute ATL (n = 5), ATL lymphoma (n = 10) and chronic/smoldering ATL (n = 2). At transplant, nine patients were in CR1, four patients were in PR and four patients had refractory disease. Median time from diagnosis to allo-SCT was 8 months (range 2-125 months). Previous therapy consisted of CHOP-like chemotherapy either alone (n = 8) or combined with bortezomib (n = 1), alemtuzumab (n = 1) or antivirals (n = 4); and salvage chemotherapy with DHAP (n = 2) or etoposide (n = 1).
Patients received myeloablative (n = 4) or reduced-intensity conditioning (n = 13) followed by HCT from an identical sibling Abbreviations: ATL = adult T-cell leukemia/lymphoma; CR1 = first CR; F/U = follow-up; m = months; NA = not applicable; PD = progressive disease. Outcome of HTLV-1-associated ATL post SCT: EBMT A Bazarbachi et al (n = 6), haploidentical relative (n = 3), matched unrelated (n = 7) or unknown donor (n = 1). Four patients developed acute GVHD (24%) and eight patients developed chronic GVHD. Eleven patients (65%) died after a median of 5 months, eight of whom (48%) following disease progression and three of whom (17%) from non-relapse transplant-related causes consisting of sepsis (n = 1) or GVHD (n = 2). Six patients (35%) are alive and the majority of them (4/6) were in CR1 at the time of allo-SCT. Threeyear EFS and OS were 25.7% (95% confidence interval, 10.1-65.6) and 34.3% (95% confidence interval, 15.5-67.2) (Figure 1) , respectively. These results are comparable with recent Japanese data [14] [15] [16] indicating that one-third of ATL patients who undergo allo-SCT will have a prolonged survival.
The fact that survivors were observed only after allo-SCT but not after auto-SCT in this and other series suggests that GVL effects are active in ATL. Of eight patients who survived 412 months post allo-SCT, six of the seven informative (missing data in one patient) patients (85%) had developed chronic GVHD in keeping with this interpretation. These results are in agreement with recent Japanese data reporting objective responses in ATL patients treated with DLI for relapse after allo-SCT. Interestingly, these responses were durable, with three cases of long-term remission of 43 years. 21 A graft vs ATL effect is also suggested by the results of the national Japanese retrospective study. 10 Non-relapse mortality was acceptable but a high rate of relapse was observed. Although based on a low number of patients, these data are consistent with those previously reported by Japanese studies. [14] [15] [16] [17] [18] Although direct comparison between two retrospective series suffers from multiple potential biases, the following observations can be made when these results are compared with those reported with antiviral therapy. 10 First, for ATL lymphoma, 3 of 10 (30%) patients are alive at 2 years with allo-SCT vs 45% with chemotherapy and 0% with AZT/IFN. Importantly, in acute ATL, one of five patients (20%) is alive at 3 years with allo-SCT vs 28% at 5 years with AZT/IFN. Finally, for acute ATL in CR1, one of three patients (33%) is alive at 3 years after allo-SCT vs 80% survival at 5 years with AZT/IFN. These results question the recommendation for mandatory allo-SCT for acute ATL patients, particularly those who achieve CR1 with antiviral therapy alone.
Overall, our results indicate that allo-SCT but not auto-SCT may salvage a subset of ATL patients, particularly those transplanted in CR1 supporting the existence of graft vs ATL effect also in non-Japanese patients. 22 
